Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Debt to Equity (2016 - 2024)

Historic Debt to Equity for Protalix BioTherapeutics (PLX) over the last 11 years, with Q2 2024 value amounting to $0.71.

  • Protalix BioTherapeutics' Debt to Equity changed N/A to $0.71 in Q2 2024 from the same period last year, while for Jun 2024 it was $0.71, marking a year-over-year change of. This contributed to the annual value of $0.6 for FY2023, which is N/A changed from last year.
  • Per Protalix BioTherapeutics' latest filing, its Debt to Equity stood at $0.71 for Q2 2024.
  • Protalix BioTherapeutics' 5-year Debt to Equity high stood at $15.21 for Q3 2021, and its period low was -$2.01 during Q4 2020.
  • Its 4-year average for Debt to Equity is $4.28, with a median of $0.7 in 2024.